Related Experiment Videos

[Warfarin fetopathy]

C Bony1, F Zyka, I Tiran-Rajaofera

  • 1Service de réanimation néonatale, CHD Félix-Guyon, 97405 Saint-Denis, La Réunion, France.

Insights

Warfarin embryopathy, a condition affecting fetuses exposed to vitamin K antagonists, presents with distinct developmental abnormalities. This case highlights chondrodysplasia punctata and facial dysmorphism in an infant exposed to acenocoumarol.

Area of Science:

  • Teratology
  • Developmental Biology
  • Pharmacology

Background:

  • Vitamin K antagonists, such as warfarin and acenocoumarol, are crucial for managing thromboembolic conditions during pregnancy.
  • However, fetal exposure can lead to a spectrum of congenital abnormalities known as warfarin embryopathy.
  • Understanding the risks and mechanisms is vital for informed clinical decision-making.

Observation:

  • A neonate exposed in utero to acenocoumarol presented with classic signs of warfarin embryopathy.
  • Clinical manifestations included chondrodysplasia punctata with telebrachydactyly, facial dysmorphism (nasal hypoplasia), cataracts, and bilateral pyeloureteral junction syndrome.
  • These findings underscore the teratogenic potential of vitamin K antagonists.

Findings:

  • Warfarin embryopathy affects over 6% of fetuses exposed to vitamin K antagonists in utero.
  • The observed anomalies represent a significant burden of disease, impacting multiple organ systems.
  • This case reinforces the diagnostic criteria for this drug-induced embryopathy.

Implications:

  • The case highlights the critical need for careful risk-benefit assessment when prescribing anticoagulants during pregnancy.
  • Further research into fetal vitamin K metabolism may elucidate the precise mechanisms underlying warfarin embryopathy.
  • Enhanced awareness among healthcare providers is essential for preventing and managing this condition.
Abstract

Related Concept Videos